Mixed Phenotype Acute Leukemia Clinical Trials

49 clinical trials for Mixed Phenotype Acute Leukemia across international registries, including 22 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) — RECRUITING · PHASE2
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant — RECRUITING · PHASE2
• Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases — RECRUITING · PHASE2
• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy — RECRUITING · PHASE3
• Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma — RECRUITING · PHASE4
• Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia — RECRUITING · PHASE3
• Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — RECRUITING · PHASE2
• A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies — RECRUITING · PHASE1
• Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT — RECRUITING · PHASE1
• A Study of Revumenib and Mezigdomide in People With Leukemia — RECRUITING · PHASE1
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia — RECRUITING · PHASE1
• The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse — RECRUITING · PHASE1
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms — RECRUITING · PHASE1
• Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) — RECRUITING · PHASE2
• A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation — RECRUITING · PHASE1
• Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL — RECRUITING · PHASE1
• Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation — RECRUITING · PHASE2
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — RECRUITING · PHASE1
• Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome — ACTIVE_NOT_RECRUITING · PHASE3
• Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
• Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies — OTHER
• Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation — ACTIVE_NOT_RECRUITING · PHASE1
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting — ACTIVE_NOT_RECRUITING · PHASE2
• First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia — WITHDRAWN · PHASE1
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE3
• Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) — SUSPENDED · PHASE1
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — ACTIVE_NOT_RECRUITING · PHASE2
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE2
• Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia — COMPLETED · PHASE1
• Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL — COMPLETED · PHASE2
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement — COMPLETED · PHASE2
• A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia — COMPLETED · PHASE1
• Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders — TERMINATED · PHASE1
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients — COMPLETED · PHASE2
• Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia — COMPLETED · PHASE2
• Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia — OTHER · PHASE1
• Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS — COMPLETED · PHASE1
• Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia — TERMINATED · PHASE1
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE2
• Management of Mixed-Phenotype Acute Leukemia in the East of France — OTHER

Refine this search